Download Citation on ResearchGate | Advances in the diagnosis, pathogenesis and treatment of CIDP | Chronic inflammatory demyelinating. This Review highlights the recent advances in diagnosing CIDP, provides an update on the immunopathology including new target antigens. CIDP is an acquired immune-mediated inflammatory disorder sometimes Advances in the diagnosis, pathogenesis and treatment of CIDP.
|Published (Last):||27 July 2006|
|PDF File Size:||1.68 Mb|
|ePub File Size:||2.60 Mb|
|Price:||Free* [*Free Regsitration Required]|
From This Paper Figures, tables, and topics from this paper. This paper treat,ent been referenced on Twitter 1 time over the past 90 days. BoumpasGeorge K.
Advances in the diagnosis, pathogenesis and treatment of CIDP
Review of the evolution of electrodiagnostic criteria for chronic inflammatory demyelinating polyradicoloneuropathy. References Publications referenced by this paper. Chronic inflammatory demyelinating polyneuropathy CIDP is the most common chronic autoimmune neuropathy.
Topics Discussed in This Paper. Showing of references. Armati Journal of the peripheral nervous system: Antonis FanouriakisDimitrios T. Showing of 60 extracted citations. Current diagnosis of CIDP: MRI assessment including apparent diffusion coefficient.
An update on the management of chronic inflammatory demyelinating polyneuropathy. This Review highlights the recent advances in diagnosing CIDP, provides an update on the immunopathology including new target antigens, and discusses current treatments, ongoing challenges and future therapeutic directions. Despite clinical challenges in diagnosis—owing in part to the existence of disease variants, and different views on how many electrophysiological abnormalities are needed to document demyelination—consensus criteria seem to have been reached for research or clinical practice.
Advances in our understanding of the underlying immunopathology in CIDP have identified new targets for future therapeutic efforts, including T cells, B cells, and transmigration and transduction molecules.
Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy Marinos C. New cido and scoring systems represent emerging tools with the potential to predict therapeutic responses and identify patients with active disease for enrollment into clinical trials.
Brannagan Journal of the peripheral nervous system: Maintenance therapy with IVIg can induce sustained remission, increase quality of life and prevent further axonal loss, but caution is needed to avoid overtreatment. John David PollardPatricia J. Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Search for additional papers on this topic.
Pathogenesis and treatment of CNS lupus. Citations Publications citing this paper. Bertsias Current opinion in rheumatology Evidence from Human and Animal Studies: Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: Skip to search form Skip to main content.
Advances in the diagnosis, pathogenesis and treatment of CIDP.
Diagnostic insights into chronic-inflammatory demyelinating polyneuropathies. Kenneth Craig Gorson Therapeutic advances in neurological disorders Commonly used immunosuppressive drugs offer minimal benefit, necessitating the development of new therapies for treatment-refractory patients.
Despite clinical challenges in diagnosis-owing in part to the existence of disease variants, and different views on how many electrophysiological abnormalities are needed to document demyelination-consensus criteria seem to have been reached pf research or clinical practice. Dalakas The Lancet Neurology